{"entity":{"id":"nct06188702","kind":"trial","name":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP","aka":[],"tldr":"A phase 1/2 trial of TNG462 in advanced solid tumours, run by Servier Bio-Innovation LLC, active and no longer recruiting.","summary":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP is a phase 1/2 interventional study registered as NCT06188702 by Servier Bio-Innovation LLC, with 60 participants enrolled, started 2024-04-29 and due to reach its primary completion in 2027-05-01. Interventions recorded: S095035 and TNG462.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06188702","url":"https://clinicaltrials.gov/study/NCT06188702"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tng462"],"companies":["tango-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06188702","phase":"1/2","setting":"A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP","sponsor":"Servier Bio-Innovation LLC","enrolled":60,"outcomes":[]},"route":"/trials/nct06188702/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"tng462","kind":"drug","name":"TNG462","route":"/drugs/tng462/"}],"company":[{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","route":"/companies/tango-therapeutics/"}]}}